Medicina clinica
-
Modulation of the immune system to prevent lung injury is being widely used against the new coronavirus disease (COVID-19). The primary endpoint was mortality at 7 days after tocilizumab administration. Secondary endpoints were admission to the intensive care unit, development of ARDS and respiratory insufficiency among others. ⋯ Early administration of tocilizumab in patients needing oxygen supplementation may be critical to patient recovery. Our preliminary data could inform bedside decisions until more data regarding the precise timing in of initiation of the treatment with tocilizumab.
-
This systematic review aims to analyze the validity and reliability of available tools to assess health-related quality of life (HRQoL) and exercise tolerance in children and adolescents with cystic fibrosis (CF). ⋯ The CFQ-R, cycloergometry and the modified shuttle test have the best properties for the assessment of children with CF, but more studies are needed.
-
Case Reports
Benefits of early use of high-flow-nasal-cannula (HFNC) in patients with COVID-19 associated pneumonia.
Severe COVID-19 is associated with hypoxemic bilateral pneumonia that leads to mechanical ventilation in a considerable proportion of patients. To the best of our knowledge, there are no recommendations about the best time to initiate high flow nasal cannula (HFNC). ⋯ Early HFNC use is associated with a decrease in the need for intubation, mortality and overall hospital stay.
-
Case Reports
Standard versus extended primary cytomegalovirus prophylaxis in solid organ transplantation.
We compared the efficacy and safety of standard vs. extended primary cytomegalovirus (CMV) prophylaxis in solid organ transplantation. ⋯ Extending primary CMV prophylaxis over 100 days did not prevent late-onset infection but it was associated with hematological toxicity.